Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Exploring the effectiveness and safety of early use of Ariceptinfen after pancreaticoduodenectomy in alleviating postoperative pain and promoting recovery of patients.
Main objective: To explore the analgesic effect of Anricfen after pancreaticoduodenectomy.
Secondary objective: To explore the impact of Anricfen on the accelerated recovery after pancreaticoduodenectomy.
Exploratory objective: To investigate the biomarkers of Anricfen's analgesic effect after pancreaticoduodenectomy, as well as its correlation factors with tumor pathology.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| experimental group | Other | Postoperatively, administer Anrikefon injection intravenously at a dose of 1 μg/kg every 8 hours for three consecutive days. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Experimental Group | Drug | Postoperatively, administer Anrikefon injection intravenously at a dose of 1 μg/kg every 8 hours for three consecutive days. |
|
| Measure | Description | Time Frame |
|---|---|---|
| The incidence of postoperative complications | After undergoing treatment for 2 months | |
| Incidence rate of adverse events | Two month after the treatment | |
| The VAS score within 0-72 hours after the operation | Within 3 days after receiving treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Changes in biochemical indicators and inflammatory indicators | The unit of C-reactive protein is mg/L;The unit of WBC is ×109/L | One week after the treatment |
| The time of first flatus and defecation after surgery, and the time to get out of bed for activities |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| yudong QIU | Contact | 0086+13809021967 | yudongqiu510@163.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| NanJing drum tower hospital | Recruiting | Nanjing | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Anrikefon | Drug | Postoperatively, intravenous injection of Anrikefon injection was administered at a dose of 1 μg/kg, every 8 hours, for three consecutive days as an intervention |
|
The time of the first postoperative standing up for activities, passing gas, and having a bowel movement is calculated in days. The postoperative hospital stay is also calculated. |
| One week after the treatment |
| Postoperative hospital stay and hospitalization costs | The postoperative hospital stay is calculated in days, and the hospitalization expenses are settled in RMB. | After undergoing treatment for 2 months |
| Postoperative analgesia satisfaction scores of the subjects and the satisfaction scores of the study doctors after the administration of the medication were obtained. | The postoperative pain relief satisfaction score and the doctor satisfaction score are calculated on a scale of 0 to 10, with 10 being the highest score. | Within 3 days after receiving treatment |
| The initial pressing time of the postoperative analgesic pump, the total number of presses, and the number of effective presses | The number of presses of the postoperative analgesic pump should be recorded based on the actual situation. Each press is counted as 1. | One day after the treatment |
| The time for discontinuing postoperative analgesics | After undergoing treatment for 2 months |
| The proportion and duration of VAS scores ≤ 3 points within 0-12 hours and 0-24 hours after the first postoperative administration | Within one day after receiving treatment |
| The timing and dosage of remedial analgesia | After undergoing treatment for 2 months |
| ID | Term |
|---|---|
| D000377 | Agnosia |
| ID | Term |
|---|---|
| D010468 | Perceptual Disorders |
| D019954 | Neurobehavioral Manifestations |
| D009461 | Neurologic Manifestations |
| D009422 | Nervous System Diseases |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided